Better Therapeutics, Inc.

Better Therapeutics, Inc. (Nasdaq: BTTX) is a prescription digital therapeutics company that became publicly traded in October 2021 through a merger with Mountain Crest Acquisition Corp. II, a blank-check company that completed its IPO in 2020 and was sponsored by Mountain Crest Capital LLC. The company operates in the digital health and cardiometabolic therapeutics sector, developing software-based treatments designed to address the behavioral and metabolic drivers of diseases such as type 2 diabetes. In December 2022, the company received FDA De Novo authorization for BT-001, its lead prescription digital therapeutic, marking a significant regulatory milestone. The annual report filed in March 2023 reflects the company's post-authorization commercial positioning. Visit SpacDesk and sign up for full SPAC filing data, sponsor histories, and deal analytics on BTTX and hundreds of other transactions.